ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Label-Free 3D Photoacoustic Imaging of Tumor Organoids for Volumetric Drug Screening.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Organoid Intelligent Morphomics: Decoding the organoid morphome through artificial intelligence from phenotypic quantification to mechanistic insight.Bioactive materials · 2027Review
- Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026Review
- Label-free ultraviolet photoacoustic microscopy for multiscale structural phenotyping of epithelial morphogenesis in organoid-derived intestinal epithelial wrinkle tissue.Photoacoustics · 2026Article
- A Label-Free Ultraviolet Photoacoustic Microscopy Enables Nuclear Imaging and Toxicity Assessment in an Intact Brain Organoid.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Deciphering Anti-Cancer Drug Efficacy Through Nanomechanical Vibrations in Living Gastric Cancer Organoids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development and application of organoid technology in pituitary neuroendocrine tumor research.The Journal of international medical research · 2026Review
- Multiscale photoacoustic imaging of stroke in preclinical models and future directions toward clinical translation [Invited].Biomedical optics express · 2026Review
- Organoids: generation strategies, applications, and future challenges.Stem cell research & therapy · 2026Review
- Soft Micromanipulation Robot for Real-Time Adaptive Multimodal Operation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- GPU-accelerated volumetric-mosaic optical-resolution photoacoustic microscopy and quantifying tumor vasculature growth.Photoacoustics · 2025Article
- From Cells to Organoids: Approaches, Regulatory Mechanisms, Applications, and Challenges of Organoids.Cells · 2025Review
- 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems.Biomedical engineering online · 2025Review
- Sophisticated Interfaces Between Biosensors and Organoids: Advancing Towards Intelligent Multimodal Monitoring Physiological Parameters.Biosensors · 2025Review
- Label-Free 3D Photoacoustic Imaging of Tumor Organoids for Volumetric Drug Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
As one of the most advanced in vitro drug screening platforms, tumor organoids require accurate pharmacosensitivity assessments to ensure reliable results. However, achieving accurate volume assessment of these 3D organoid models remains a challenge in traditional drug screening processes. Here, a label-free organoids photoacoustic imaging (LFOPI) system is introduced for high-resolution 3D imaging of tumor organoids. The capabilities of the LFOPI system are evaluated by monitoring structural transformations in melanoma organoids. The LFOPI system is further employed for volumetric drug screening of melanoma tumor organoids. Drug screening with cisplatin and temozolomide reveal that LFOPI-based organoid volume data correlates more strongly with viability trends (0.8627 and 0.9069) than traditional diameter-based methods (0.8190 and 0.7849). Additionally, immunotherapy drug screening demonstrates the capability of the system to precisely assess the 3D volumes of irregularly shaped organoids. This LFOPI system provides a promising method for label-free drug screening and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.